

Solid Tumor NGS Panel: Resumption of In-House Testing and Change in Assay Platform

Date: April 30th, 2025

Effective Date: July 16th, 2025

The Molecular Diagnostic Laboratory will resume in-house testing for solid tumor NGS. Prior to the use of the Mayo Complete Solid Tumor Panel (MCSTP) for send-outs, the laboratory previously conducted testing with the Thermo Fisher Oncomine Focus Assay (STMP). Starting July 16th, 2025, testing will be performed in-house using the Oncomine Precision Assay (OPAST).

OPAST will be run on the Thermo Fisher Genexus platform, which provides advantages such as a highly automated workflow and significantly faster turnaround times.

OPAST expands coverage from 35 genes to 45 genes. The new panel includes coverage of hotspot regions in the following genes: *AKT2*, *AKT3*, *ARAF*, *CDKN2A*, *CHEK2*, *FGFR1*, *FGFR4*, *FLT3*, *GNAS*, *NTRK1*, *NTRK2*, *NTRK3*, *PTEN*, and *TP53*. Genes that were covered by STMP but no longer covered by OPAST are *DDR2*, *JAK1*, *JAK2*, and *JAK3*.

Oncomine Precision Assay Gene List:

DNA Hotspots				
AKT1	CHEK2	FGFR3	KIT	NTRK3
AKT2	CTNNB1	FGFR4	KRAS	PDGFRA
AKT3	EGFR	FLT3	MAP2K1	PIK3CA
ALK	ERBB2	GNA11	MAP2K2	PTEN
AR	ERBB3	GNAQ	MET	RAF1
ARAF	ERBB4	GNAS	MTOR	RET
BRAF	ESR1	HRAS	NRAS	ROS1
CDK4	FGFR1	IDH1	NTRK1	SMO
CDKN2A	FGFR2	IDH2	NTRK2	TP53

Note: Please request OPAST along with GNFS (Lung Cancer Gene Fusion Panel) when appropriate.

For any questions, please contact:

From: Zoltan Oltvai, M.D.

Director of the Molecular Diagnostic Laboratory

UR Medicine Labs Phone: (585) 273-2229

Email: Zoltan Oltvai@urmc.rochester.edu

Paige Elliott

Supervisor, Molecular Diagnostic Laboratory

Phone: (585) 275-2709

Email: Paige_Elliott@urmc.rochester.edu